OBJECTIVES: Despite increasing interest, prospective data on the use of degradable starch microsphere-transarterial chemoembolization (DSM-TACE) in the management of patients with unresectable HCC are still scarce. The objective of the HepaStar study was to collect prospective safety and effectiveness data in a prospective multicenter observational study. MATERIALS AND METHODS: Between January 2017 and December 2022, consecutive participants with unresectable or recurrent HCC treated with DSM-TACE as standard of care at 6 participating centers in Europe were enrolled. Tumor response was evaluated according to the mRECIST criteria. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were assessed by using Kaplan-Meier analysis and Common Terminology Criteria for Adverse Events, version 5. Liver function deterioration was assessed by monitoring changes in liver blood tests during the follow-up. RESULTS: Seventy-nine participants (median age, 69 years (IQR, 51-87 years); 67 men (85%)) were enrolled and treated. The median follow-up time was 18 months (IQR 9.5-38.0 months). The estimated median OS and PFS for the entire cohort was 32 months (CI, 95% 21-NaN) and 9 months (CI, 95% 7-NaN), respectively. Eleven (13.9%) participants experienced at least one grade 3 or 4 AE. The most frequent grade 3-4 AE was elevated bilirubin (2.2%, 5 of 79). Deterioration of bilirubin, AST, ALT, and albumin were observed in 24.1%, 23.7%, 19%, and 24% of participants, respectively. CONCLUSION: DSM-TACE achieves promising survival in patients with unresectable or recurrent HCC. This technique shows a favorable safety profile both in terms of treatment-related AEs and liver function deterioration. KEY POINTS: Question Although degradable starch microspheres transarterial chemoembolization is widely used in clinical practice across Europe, prospective data on its application in hepatocellular carcinoma patients remains limited. Findings Degradable starch microspheres transarterial chemoembolization results in promising survival rates, good tumor response rates, and low rates of treatment-related adverse events. Clinical relevance In patients with unresectable hepatocellular carcinoma, degradable starch microspheres transarterial chemoembolization represents a safe and effective alternative to more well-established chemoembolization techniques like conventional transarterial chemoembolization and drug-eluting beads transarterial chemoembolization.

Berlin Institute of Health Anna Louisa Karsch Straße 2 10178 Berlin Germany

Clinic of Radiology University Hospital of Münster Albert Schweitzer Campus 1 48149 Münster Germany

Department of Diagnostic and Interventional Radiology Göttlicher Heiland Krankenhaus Dornbacher Straße 20 30 1170 Wien Austria

Department of Radiology and Nuclear Medicine University Hospital Brno and Masaryk University Jihlavská 340 20 625 00 Brno Czech Republic

Department of Radiology Charité University Medicine Berlin Berlin Charitéplatz 1 10117 Berlin Germany

Department of Radiology Klinikum Karlsruhe Moltkestraße 90 76133 Karlsruhe Germany

Department of Radiology University Hospital LMU Munich Marchioninistraße 15 81377 Munich Germany

Department of Radiology University Medical Center Regensburg Franz Josef Strauß Allee 11 93053 Regensburg Germany

Zobrazit více v PubMed

Akinyemiju T, Abera S, Ahmed M et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3:1683–1691 PubMed PMC

Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6 PubMed

Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–693 PubMed PMC

de Baere T, Arai Y, Lencioni R et al (2016) Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol 39:334–343 PubMed

Facciorusso A (2018) Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol 24:161–169 PubMed PMC

Schicho A, Pereira PL, Pützler M et al (2017) Degradable starch microspheres transcatheter arterial chemoembolization (DSM-TACE) in intrahepatic cholangiocellular carcinoma (ICC): results from a National Multi-Center Study on Safety and Efficacy. Med Sci Monit 23:796–800 PubMed PMC

Pieper CC, Meyer C, Vollmar B, Hauenstein K, Schild HH, Wilhelm KE (2015) Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept®S) in a swine model. Cardiovasc Intervent Radiol 38:435–441 PubMed

Ludwig JM, Iezzi R, Theysohn JM, Albrecht T, Posa A, Gross A (2021) European multicenter study on degradable starch microsphere TACE: the digestible way to conquer HCC in patients with high tumor burden. Cancers (Basel) 13:5122 PubMed PMC

Auer TA, Jonczyk M, Collettini F et al (2021) Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol 62:313–321 PubMed

Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S (2020) Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. Radiol Med 125:98–106 PubMed

Orlacchio A, Chegai F, Francioso S et al (2018) Repeated transarterial chemoembolization with degradable starch microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study. Curr Med Imaging Rev 14:637–645 PubMed PMC

Iezzi R, Pompili M, Rinninella E et al (2019) TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol 29:1285–1292 PubMed

Gross A, Albrecht T (2020) Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacy. Cardiovasc Intervent Radiol 43:402–410 PubMed

Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T (2021) CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol 44:1851–1867 PubMed

Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F (2019) Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 19:795 PubMed PMC

Schicho A, Pereira PL, Haimerl M et al (2017) Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget 8:72613–72620 PubMed PMC

Haubold J, Reinboldt MP, Wetter A et al (2020) DSM-TACE of HCC: evaluation of tumor response in patients ineligible for other systemic or loco-regional therapies. Rofo 192:862–869 PubMed

Niessen C, Unterpaintner E, Goessmann H et al (2014) Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 25:240–247 PubMed

Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52 PubMed PMC

Auer TA, Müller L, Schulze D et al (2024) CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Radiology 310:e232044 PubMed

Han G, Berhane S, Toyoda H et al (2020) Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 72:198–212 PubMed PMC

Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64:106–116 PubMed

Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264 PubMed PMC